ClinicalTrials.gov
ClinicalTrials.gov Menu

Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00698074
Recruitment Status : Unknown
Verified June 2008 by University Hospital Birmingham.
Recruitment status was:  Recruiting
First Posted : June 16, 2008
Last Update Posted : June 16, 2008
Sponsor:
Information provided by:
University Hospital Birmingham

Brief Summary:
The primary aim of this study will be to assess whether Biventricular pacing improves exercise capacity, and Quality of Life in patients with symptomatic drug resistant Non-Obstructive Hypertrophic Cardiomyopathy, using a Biventricular pacemaker.

Condition or disease Intervention/treatment Phase
Hypertrophic Cardiomyopathy Device: Cardiac Resynchronisation Therapy Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy


Arm Intervention/treatment
Experimental: 1
Cardiac Resynchronisation Therapy
Device: Cardiac Resynchronisation Therapy
Biventricular Pacemaker Implant





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Symptomatic Hypertrophic Cardiomyopathy,

Exclusion Criteria:

  • Rhythm other than normal sinus Left ventricular outflow tract gradient greater than 30mmHg Inability to exercise v02 max greater than 70% of predicted.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00698074


Contacts
Contact: Michael P Frenneaux, MBBS 121-414-5916 ext 5916 m.p.frenneaux@bham.ac.uk

Locations
United Kingdom
Department Cardiovascular Medicine, University of Birmingham Recruiting
Birmingham, West Midlands, United Kingdom, B15 2TT
Contact: ibrar ahmed, MBChB    121-414-5916    01ahmedi@gmail.com   
Sponsors and Collaborators
University Hospital Birmingham

ClinicalTrials.gov Identifier: NCT00698074     History of Changes
Other Study ID Numbers: 05/Q2709/64
First Posted: June 16, 2008    Key Record Dates
Last Update Posted: June 16, 2008
Last Verified: June 2008

Additional relevant MeSH terms:
Cardiomyopathies
Hypertrophy
Cardiomyopathy, Hypertrophic
Heart Diseases
Cardiovascular Diseases
Pathological Conditions, Anatomical
Aortic Stenosis, Subvalvular
Aortic Valve Stenosis
Heart Valve Diseases